Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
CDXS's Cash to Debt is ranked higher than
78% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CDXS: No Debt )
CDXS' s 10-Year Cash to Debt Range
Min: 2.71   Max: No Debt
Current: No Debt

Equity to Asset 0.65
CDXS's Equity to Asset is ranked higher than
70% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CDXS: 0.65 )
CDXS' s 10-Year Equity to Asset Range
Min: -1.82   Max: 0.79
Current: 0.65

-1.82
0.79
F-Score: 2
Z-Score: -5.55
M-Score: -3.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -128.90
CDXS's Operating margin (%) is ranked higher than
67% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CDXS: -128.90 )
CDXS' s 10-Year Operating margin (%) Range
Min: -155.16   Max: -6.65
Current: -128.9

-155.16
-6.65
Net-margin (%) -129.39
CDXS's Net-margin (%) is ranked higher than
67% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CDXS: -129.39 )
CDXS' s 10-Year Net-margin (%) Range
Min: -153.96   Max: -7.97
Current: -129.39

-153.96
-7.97
ROE (%) -99.57
CDXS's ROE (%) is ranked higher than
56% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CDXS: -99.57 )
CDXS' s 10-Year ROE (%) Range
Min: -99.57   Max: -7.96
Current: -99.57

-99.57
-7.96
ROA (%) -70.20
CDXS's ROA (%) is ranked higher than
57% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CDXS: -70.20 )
CDXS' s 10-Year ROA (%) Range
Min: -70.2   Max: -6.04
Current: -70.2

-70.2
-6.04
ROC (Joel Greenblatt) (%) -487.17
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CDXS: -487.17 )
CDXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -487.17   Max: -33.21
Current: -487.17

-487.17
-33.21
Revenue Growth (%) -42.40
CDXS's Revenue Growth (%) is ranked higher than
59% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CDXS: -42.40 )
CDXS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -42.4
Current: -42.4

EPS Growth (%) 45.60
CDXS's EPS Growth (%) is ranked higher than
97% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CDXS: 45.60 )
CDXS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 45.6
Current: 45.6

0
45.6
» CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CDXS Guru Trades in Q2 2013

Jim Simons 158,900 sh (+151.5%)
» More
Q3 2013

CDXS Guru Trades in Q3 2013

Jim Simons 84,100 sh (-47.07%)
» More
Q4 2013

CDXS Guru Trades in Q4 2013

Jim Simons 246,943 sh (+193.63%)
» More
Q1 2014

CDXS Guru Trades in Q1 2014

Jim Simons 196,292 sh (-20.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.0012%$4.24 - $6.02 $ 1.94-26%0
George Soros 2011-09-30 New Buy$4.39 - $10.24 $ 1.94-72%14800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
CDXS's P/B is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CDXS: 2.00 )
CDXS' s 10-Year P/B Range
Min: 0.83   Max: 3.96
Current: 2

0.83
3.96
P/S 2.71
CDXS's P/S is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CDXS: 2.71 )
CDXS' s 10-Year P/S Range
Min: 0.27   Max: 3.53
Current: 2.71

0.27
3.53
EV-to-EBIT -1.36
CDXS's EV-to-EBIT is ranked higher than
73% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CDXS: -1.36 )
CDXS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.36

Current Ratio 2.62
CDXS's Current Ratio is ranked higher than
65% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CDXS: 2.62 )
CDXS' s 10-Year Current Ratio Range
Min: 1.14   Max: 3.98
Current: 2.62

1.14
3.98
Quick Ratio 2.46
CDXS's Quick Ratio is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CDXS: 2.46 )
CDXS' s 10-Year Quick Ratio Range
Min: 1.07   Max: 3.75
Current: 2.46

1.07
3.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.20
CDXS's Price/Net Cash is ranked higher than
79% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. CDXS: 16.20 )
CDXS' s 10-Year Price/Net Cash Range
Min: 3.45   Max: 20.06
Current: 16.2

3.45
20.06
Price/Net Current Asset Value 7.80
CDXS's Price/Net Current Asset Value is ranked higher than
85% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. CDXS: 7.80 )
CDXS' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 12.35
Current: 7.8

2.76
12.35
Price/Tangible Book 3.00
CDXS's Price/Tangible Book is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CDXS: 3.00 )
CDXS' s 10-Year Price/Tangible Book Range
Min: 1.34   Max: 4.84
Current: 3

1.34
4.84
Price/Median PS Value 2.10
CDXS's Price/Median PS Value is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CDXS: 2.10 )
CDXS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 2.58
Current: 2.1

0.24
2.58
Forward Rate of Return (Yacktman) -118.62
CDXS's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CDXS: -118.62 )
CDXS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 49.2   Max: 52
Current: -118.62

49.2
52

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4QK.Germany
Codexis, Inc. was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. The Company is currently selling its biocatalysts to customers in the pharmaceutical industry and is engaged in a multi-year research and development collaboration with Equilon Enterprises LLC dba Shell Oil Products US ('Shell') to develop advanced biofuels. The Company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. Biocatalysts are enzymes or microbes that initiate or accelerate chemical reactions. It has focused its biocatalyst development efforts on large and rapidly growing markets, including pharmaceuticals and advanced biofuels. It has enabled biocatalyst-based drug manufacturing processes at commercial scale and has delivered biocatalysts and drug products to some of the world's pharmaceutical companies, including Dr. Reddy's Laboratories Ltd., Merck & Co., Inc., Pfizer Inc. and Ranbaxy Laboratories Limited. In the Company's research and development collaboration with Shell, it is developing biocatalysts for use in producing advanced biofuels from renewable sources of non-food plant materials, known as cellulosic biomass. It faces intense competition in the pharmaceuticals market. The Company's registered and pending U.S. trademarks include Codexis, Codex and Codex Biocatalyst Panel. The Codexis and Codexis design marks have been registered or are pending in selected foreign countries.
» More Articles for CDXS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
comment on CDXS Mar 23 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer Jul 28 2014
CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,... Jul 28 2014
4:02 pm Codexis names Gordon Sangster Senior VP and CFO Jul 28 2014
Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer Jul 28 2014
Why Codexis (CDXS) Stock Hit a One-Year High Today Jul 15 2014
Codexis Inc Announces Technology Collaboration and License Agreement With GSK Call scheduled for... Jul 15 2014
Codexis Announces Technology Collaboration and License Agreement With GSK Jul 14 2014
CODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 14 2014
Codexis Announces Technology Collaboration and License Agreement With GSK Jul 14 2014
CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 30 2014
CODEXIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 13 2014
CODEXIS INC Financials May 16 2014
CODEXIS INC Files SEC form 10-Q, Quarterly Report May 08 2014
Codexis' (CDXS) CEO John Nicols on Q1 2014 Results - Earnings Call Transcript May 07 2014
Codexis, Inc. Earnings Call scheduled for 4:30 pm ET today May 07 2014
CODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2014
Codexis Reports Financial Results for the First Quarter of 2014 May 07 2014
Q1 2014 Codexis, Inc. Earnings Release - After Market Close May 07 2014
Codexis to Announce First Quarter 2014 Financial Results on May 7, 2014 Apr 30 2014
LifeSci Advisors Initiates Coverage of Codexis, Inc. Apr 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide